Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66


Enlightening discriminative network functional modules behind Principal Component Analysis separation in differential-omic science studies.

Ciucci S, Ge Y, Durán C, Palladini A, Jiménez-Jiménez V, Martínez-Sánchez LM, Wang Y, Sales S, Shevchenko A, Poser SW, Herbig M, Otto O, Androutsellis-Theotokis A, Guck J, Gerl MJ, Cannistraci CV.

Sci Rep. 2017 Mar 13;7:43946. doi: 10.1038/srep43946.


CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.

Cheng Z, Shan F, Yang Y, Shi Y, Zhang Z.

BMC Med Imaging. 2017 Jan 10;17(1):5. doi: 10.1186/s12880-016-0175-3.


Determining lower limits of detection of digital PCR assays for cancer-related gene mutations.

Milbury CA, Zhong Q, Lin J, Williams M, Olson J, Link DR, Hutchison B.

Biomol Detect Quantif. 2014 Aug 20;1(1):8-22.


Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.

Schabath MB, Cress D, Munoz-Antonia T.

Cancer Control. 2016 Oct;23(4):338-346.


Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation.

Nurwidya F, Takahashi F, Takahashi K.

J Nat Sci Biol Med. 2016 Jul-Dec;7(2):119-23. doi: 10.4103/0976-9668.184695. Review.


Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.

Xie J, Lu X, Wu X, Lin X, Zhang C, Huang X, Chang Z, Wang X, Wen C, Tang X, Shi M, Zhan Q, Chen H, Deng X, Peng C, Li H, Fang Y, Shao Y, Shen B.

Mol Genet Genomic Med. 2016 Jan 10;4(3):262-72. doi: 10.1002/mgg3.201.


Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.

Bansal P, Osman D, Gan GN, Simon GR, Boumber Y.

Front Oncol. 2016 May 4;6:112. doi: 10.3389/fonc.2016.00112. Review.


BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.

Li Y, Deutzmann A, Choi PS, Fan AC, Felsher DW.

Oncotarget. 2016 May 10;7(19):26926-34. doi: 10.18632/oncotarget.8731.


Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth.

Wang H, Wang L, Zhang Y, Wang J, Deng Y, Lin D.

Cancer Cell Int. 2016 Feb 16;16:9. doi: 10.1186/s12935-016-0280-y. Erratum in: Cancer Cell Int. 2016;16:38.


Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.

Duong-Ly KC, Devarajan K, Liang S, Horiuchi KY, Wang Y, Ma H, Peterson JR.

Cell Rep. 2016 Feb 2;14(4):772-81. doi: 10.1016/j.celrep.2015.12.080.


EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J.

Cancer Res. 2016 Jan 15;76(2):305-18. doi: 10.1158/0008-5472.CAN-15-0717.


A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.

Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013.


EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.

Zhang H, Zhan C, Ke J, Xue Z, Zhang A, Xu K, Shen Z, Yu L, Chen L.

Oncotarget. 2016 Jan 19;7(3):3367-78. doi: 10.18632/oncotarget.6491.


Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.

Lovly CM.

Am Soc Clin Oncol Educ Book. 2015:e165-73. doi: 10.14694/EdBook_AM.2015.35.e165. Review.


Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancer.

Müller CB, De Bastiani MA, Becker M, França FS, Branco MA, Castro MA, Klamt F.

Oncotarget. 2015 Feb 28;6(6):3531-9.


Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

Hirsh V, Blais N, Burkes R, Verma S, Croitoru K.

Curr Oncol. 2014 Dec;21(6):329-36. doi: 10.3747/co.21.2241.


Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.

Jung SK, Lee MH, Lim DY, Kim JE, Singh P, Lee SY, Jeong CH, Lim TG, Chen H, Chi YI, Kundu JK, Lee NH, Lee CC, Cho YY, Bode AM, Lee KW, Dong Z.

J Biol Chem. 2014 Dec 26;289(52):35839-48. doi: 10.1074/jbc.M114.585513.


MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M.

Clin Cancer Res. 2015 Apr 15;21(8):1935-43. doi: 10.1158/1078-0432.CCR-14-2124.

Supplemental Content

Support Center